18 Jul 2024
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease
|
20103010 Biotechnology |
Other subject |
09 Jul 2024
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease
|
20103010 Biotechnology |
Other subject |
21 Jun 2024
15:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
|
20103010 Biotechnology |
General meeting / Board Meeting |
23 May 2024
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
|
20103010 Biotechnology |
Corporate life |
15 May 2024
07:00 CEST |
VIVORYON |
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
|
20103010 Biotechnology |
Corporate life |
08 May 2024
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
24 Apr 2024
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
|
20103010 Biotechnology |
Corporate life |
16 Apr 2024
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
|
20103010 Biotechnology |
Other subject |
15 Mar 2024
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
|
20103010 Biotechnology |
Corporate life |
04 Mar 2024
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
|
20103010 Biotechnology |
Corporate life |
08 Jan 2024
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
|
20103010 Biotechnology |
Meetings / events |
06 Dec 2023
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
|
20103010 Biotechnology |
Corporate life |
28 Nov 2023
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
|
20103010 Biotechnology |
Other subject |
07 Nov 2023
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
|
20103010 Biotechnology |
Meetings / events |
26 Oct 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
|
20103010 Biotechnology |
Other subject |
23 Oct 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
|
20103010 Biotechnology |
Other subject |
17 Oct 2023
15:32 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
|
20103010 Biotechnology |
Meetings / events |
05 Oct 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation
|
20103010 Biotechnology |
Other subject |
15 Sep 2023
13:57 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board
|
20103010 Biotechnology |
General meeting / Board Meeting |
07 Sep 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
|
20103010 Biotechnology |
Other subject |
31 Aug 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023
|
20103010 Biotechnology |
Other subject |
04 Aug 2023
23:35 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
|
20103010 Biotechnology |
General meeting / Board Meeting |
04 Aug 2023
23:30 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
|
20103010 Biotechnology |
Other subject |
16 Jul 2023
09:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
|
20103010 Biotechnology |
Corporate life |
21 Jun 2023
18:02 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
|
20103010 Biotechnology |
General meeting / Board Meeting |
15 Jun 2023
17:49 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
|
20103010 Biotechnology |
Other subject |
01 Jun 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
|
20103010 Biotechnology |
Meetings / events |
26 May 2023
07:39 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million
|
20103010 Biotechnology |
Change in Capital |
25 May 2023
17:50 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering
|
20103010 Biotechnology |
Other financial transaction |
16 May 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress
|
20103010 Biotechnology |
Other subject |
09 May 2023
07:02 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023
|
20103010 Biotechnology |
General meeting / Board Meeting |
09 May 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023
|
20103010 Biotechnology |
Other subject |
01 May 2023
10:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
|
20103010 Biotechnology |
Other subject |
24 Apr 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
|
20103010 Biotechnology |
Other subject |
19 Apr 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress
|
20103010 Biotechnology |
Other subject |
14 Apr 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023
|
20103010 Biotechnology |
Other subject |
28 Mar 2023
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease
|
20103010 Biotechnology |
Other subject |
21 Feb 2023
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
|
20103010 Biotechnology |
Meetings / events |
03 Feb 2023
14:32 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference
|
20103010 Biotechnology |
Meetings / events |
28 Nov 2022
13:30 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
|
20103010 Biotechnology |
Meetings / events |
23 Nov 2022
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
|
20103010 Biotechnology |
Other subject |
22 Nov 2022
07:20 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
|
20103010 Biotechnology |
Other subject |
14 Nov 2022
07:00 CET |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
|
20103010 Biotechnology |
Other subject |
30 Sep 2022
08:47 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
|
20103010 Biotechnology |
Commercial results |
30 Sep 2022
08:45 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
|
20103010 Biotechnology |
Change in Capital |
26 Sep 2022
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
|
20103010 Biotechnology |
Other subject |
31 Jul 2022
18:05 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
|
20103010 Biotechnology |
Trends / Analyses |
31 Jul 2022
18:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
|
20103010 Biotechnology |
Trends / Analyses |
23 Jun 2022
07:00 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD
|
20103010 Biotechnology |
Trends / Analyses |
22 Jun 2022
19:13 CEST |
VIVORYON THERAPEUTICS N.V. |
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022
|
20103010 Biotechnology |
General meeting / Board Meeting |